Aura Biosciences
Aura Biosciences
AURA
NASDAQ
7.49
USD
0.00%
About
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response.
Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules.
It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 110.2K |
| Three Month Average Volume | 3.8M |
| High Low | |
| Fifty-Two Week High | 12.35 USD |
| Fifty-Two Week Low | 5.99 USD |
| Fifty-Two Week High Date | 06 Nov 2023 |
| Fifty-Two Week Low Date | 07 Nov 2023 |
| Price and Volume | |
| Current Price | 7.95 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -18.56% |
| Thirteen Week Relative Price Change | 1.06% |
| Twenty-Six Week Relative Price Change | -21.75% |
| Fifty-Two Week Relative Price Change | -38.88% |
| Year-to-Date Relative Price Change | -24.23% |
| Price Change | |
| One Day Price Change | 1.27% |
| Thirteen Week Price Change | 8.16% |
| Twenty-Six Week Price Change | -13.96% |
| Five Day Price Change | 4.74% |
| Fifty-Two Week Price Change | -23.41% |
| Year-to-Date Price Change | -10.27% |
| Month-to-Date Price Change | -22.14% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.57638 USD |
| Book Value Per Share (Most Recent Quarter) | 3.86126 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.57638 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.86126 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.95787 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.92852 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.78939 USD |
| Normalized (Last Fiscal Year) | -1.93193 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.92852 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.78939 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.92852 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.78939 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.5825 USD |
| Cash Per Share (Most Recent Quarter) | 3.77982 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.89571 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.74538 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.63642 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 15.09% |
| EPS Change (Trailing Twelve Months) | 10.80% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -187,416,000 |
| Net Debt (Last Fiscal Year) | -226,150,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 19 |
| Current Ratio (Most Recent Quarter) | 19 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -64,556,000 |
| Free Cash Flow (Trailing Twelve Months) | -74,390,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -31.90% |
| Return on Assets (Trailing Twelve Months) | -39.26% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -36.26% |
| Return on Equity (Trailing Twelve Months) | -45.09% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -33.50% |
| Return on Investment (Trailing Twelve Months) | -41.21% |
| Return on Investment (5 Year) | -99,999.99% |